

1 *Plos One*

2 **Mapping evidence on cryptococcal antigen infection among HIV-infected**
3 **persons in sub-Saharan Africa- A Scoping Review Protocol**

4 Khululiwe Dlamini¹, Boitumelo Moetlhoa¹, Astrid Turner¹, Kuhlula Maluleke¹ and
5 Tivani Mashamba-Thompson²

6

7 ¹School of Health Systems and Public Health, Faculty of Health Sciences, University
8 of Pretoria, Pretoria, South Africa

9 ²Faculty of Health Sciences, University of Pretoria, South Africa

10

11 Corresponding author: Boitumelo Moetlhoa

12

13 ¹School of Health Systems of Public Health, Faculty of Health Sciences, University of
14 Pretoria, South Africa

15

16 Email: u22029992@tuks.co.za

17

18 **Abstract**

19

20 **Introduction:** Infections of the central nervous system are a considerable basis of
21 mortality in people living with Human immunodeficiency virus (HIV), with progression
22 to cryptococcal meningitis documented at around 15% of HIV-associated mortality
23 globally, with nearly three-quarters occurring in the sub-Saharan Africa. Discoveries
24 from previous studies precluded that mortality amid cryptococcal antigen (CrAg)
25 positive persisted to be elevated than in CrAg negative persons. One feasible
26 interpretation of this could be due to undiagnosed cryptococcus. Laboratory
27 investigations towards prompt identification of cryptococcal disease prior to
28 cryptococcal meningitis has progressed to point-of-care testing with high sensitivity
29 and specificity as seen with the CrAg lateral flow assay screening to expedite
30 treatment. The aim of the study is to map and translate evidence on CrAg infection
31 among HIV-infected persons in sub-Saharan Africa (SSA).

32 **Methodology:** The proposed scoping review will be conducted using guidelines
33 proposed by Arksey and O'Malley methodological framework and Levac et al
34 advanced method. It will be guided by the Preferred Reporting Items for Systematic
35 Reviews and Meta-Analysis for Scoping Reviews. A comprehensive literature search
36 of studies published from the first relevant publication to 2022 will be conducted on
37 multiple electronic databases. Additional sources (grey literature) will also be
38 searched. The search strategy will be generated and implemented by the principal
39 investigator with assistance from a subject specialist, and an information specialist.
40 Two reviewers will screen eligible studies. The screening will be guided by an inclusion
41 and exclusion criteria. The mixed method appraisal tool (MMAT) version 2018 will be
42 used to appraise the quality of the empirical studies.

43 **Discussion:** The proposed scoping review will map and translate evidence on CrAg
44 infection among HIV-infected persons in sub-Saharan Africa. Synthesising and
45 sharing recent evidence in this area has potential to help guide future research and
46 interventions aimed at improving the management of CrAg infection among HIV-
47 infected persons in sub-Saharan Africa and other high HIV- burdened settings.

48 **Keywords:** Human immunodeficiency virus, cryptococcal antigen, sub-Saharan
49 Africa

50 Introduction

51 Cryptococcal disease is a paramount cause of illness in people living with HIV/AIDS
52 and has major consequences if left undiagnosed and untreated. An approach to
53 identifying risk of progression to disease is necessary to guide CrAg screening in the
54 distribution of resources particularly in resource-limited settings when supervising
55 people demonstrating advanced HIV disease. Updated guidelines are required to
56 provide recommendations on approach to detection, diagnosis and treatment. These
57 guidelines also include strategies on preventing invasive illness and potential impact
58 with antiretroviral therapy (ART). When cryptococcal disease is suspected, the CrAg
59 point-of-care (POC) testing is conducted to enable prompt treatment before the
60 progression to cryptococcal meningitis (CM). CM is the most common appearance of
61 the infection and a contributing factor to the morbidity and mortality in the SSA.
62 Mortality is further increased through the immediate initiation of ART in people living
63 with HIV (PLHIV) that have been diagnosed with CM. The guidelines recommended
64 by the World Health Organisation (WHO), is to delay ART by 4–6 weeks from the
65 initiation of antifungal treatment (1, 2).

66 Discovering the estimates of incidence and prevalence of HIV-related diseases
67 specially in cryptococcal infection has been continuous in studies globally (3-6),
68 despite the advancement of HIV management and medicine. The global burden
69 estimates have important purpose in recommended guidelines for prevention
70 strategies required for treatment. Studies were conducted on “the prevalence of
71 cryptococcal infection among HIV-persons with a CD4 cell count of less than 100
72 cells/ μ L” however, the clinical characteristics of PLHIV, with the progression to CM
73 proportional with elevated CD4 cell counts (101-200 cells/ μ L), would contribute
74 discernment into the role of the immune response to the pathogenesis of CM. This
75 enables customization of applicable treatment interventions for cryptococcosis (1).
76 Identified patients begin pre-emptive therapy with a high concentrated dosage of
77 fluconazole to inhibit development of severe disease (1, 7, 8). A CD4 cell count is a
78 necessary tool in aiding decision-makers in clinical management (9). A CD4 cell count
79 of less than 200 cells/ μ L is regarded a threshold for potential morbidity (10). The WHO
80 recommends screening for CrAg in PLHIV, followed by pre-emptive antifungal
81 treatment for a positive screening, to prevent progression to CM. This

82 recommendation is for adults and adolescents living with HIV before the initiation or
83 re-initiation of ART therapy (2). One study publicized that in Africa, the cryptococcosis-
84 associated immune reconstitution inflammatory syndrome (IRIS) is dangerous with 27-
85 83% reported mortalities, this would be due to undiagnosed cryptococcosis. Additional
86 studies would be necessary to further understand the perseverance of high mortality
87 in the context of establishing appropriate strategies in screening for CM within routine
88 testing (7). Laboratory investigations towards early detection of cryptococcal disease
89 prior to CM has progressed to POC testing with high sensitivity and specificity as seen
90 with the CrAg lateral flow assay (CrAg LFA) screening to expedite treatment (9, 11),
91 therefore the level of evidence to validate clinic-based CrAg LFA testing in sub-
92 Saharan Africa (SSA) is not clear (12). The proposed scoping review aims to
93 systematically map evidence on CrAg infection among HIV-infected persons in sub-
94 Saharan Africa. It is anticipated that findings from this study will contribute evidence
95 to propose improved management of CrAg infections within healthcare in SSA.

96

97 **Methodology**

98 The scoping review will be performed using guidelines proposed by Arksey and
99 O'Malley (14) methodological framework and Levac et al advanced method (15) and
100 guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis
101 for Scoping Reviews (PRISMA-ScR) (16, 17). The five stages of Arksey and O'Malley
102 framework that will be used to perform this scoping review are: i) identifying the
103 research question ii) identifying relevant studies iii) eligible study selection iv) charting
104 the data and v) collating, summarising and reporting the results. This scoping review
105 will not incorporate stage six involving stakeholders' consultation.

106 **i. Identifying the research question**

107 The research question is: What is the level of evidence on CrAg infection among HIV-
108 infected persons in SSA? To Refine the research question for the scoping review we
109 will use the Population, Concept, Context (PCC) nomenclature summarized in table 1
110 below.

111 **Table 1:** PCC framework for refining the research question

Population	HIV-infected persons all infected people
Concept	CrAg infection Opportunistic fungal agent resulting in HIV-related infection (18)
Context	sub-Saharan Africa

112

113 **ii. Identifying relevant studies**

114 Comprehensive literature searches of studies published from the first relevant
115 publication to 2022 will be conducted on the following electronic databases from
116 Scopus, PubMed, and EBSCO host (MEDLINE, Cumulative Index to Nursing and
117 Allied Health Literature (CINAHL). Additionally, we will look at grey literature (university

118 dissertations and thesis), government and international organisations such as WHO
119 reports to determine more sources of information that have not been arranged by
120 electronic databases. We will manually search for references cited in the included
121 articles. The English language will be applied.

122 A comprehensive literature search strategy combining terms will be done in three
123 separate searches: “HIV” “PLHIV” “HIV infected persons” “advance HIV disease” “HIV
124 related disease”, “Cryptococcal” “Cryptococcus” “Cryptococcosis” “Cryptococcal
125 antigen” “Cryptococcal antigen infection” “CrAg” “CrAg screening” “Cryptococcal
126 meningitis” “Meningitis”, and “Sub-Saharan Africa” “SSA”.

127 The search strategy will be created and implemented by the principal investigator (PI)
128 with assistance from a subject specialist, and an information specialist (university
129 librarian). Each database search will be on record to show the following: date of
130 search, electronic database, keywords/MeSH terms, and the number of recovered
131 studies. A pilot search was conducted on one of the electronic databases and the
132 findings are documented in table 2 below. To confirm accurate use of terminology,
133 keywords may be edited to ensure database search suitability.

134 **Table 2: Results of pilot search**

Date of search	Electronic Database	Keywords/MeSH terms	Number of hits
05/10/2022	PubMed	HIV: "hiv"[MeSH Terms] OR "hiv"[All Fields] cryptococcal: "cryptococcus"[MeSH Terms] OR "cryptococcus"[All Fields] OR "cryptococcal"[All Fields] infection: "infect"[All Fields] OR "infectability"[All Fields] OR "infectable"[All Fields] OR "infectant"[All Fields] OR "infectants"[All Fields] OR "infected"[All Fields] OR "infecteds"[All Fields] OR "infectibility"[All Fields] OR "infectible"[All Fields] OR "infecting"[All Fields] OR "infection's"[All Fields] OR "infections"[MeSH Terms] OR "infections"[All Fields] OR	485

		"infection"[All Fields] OR "infective"[All Fields] OR "infectiveness"[All Fields] OR "infectives"[All Fields] OR "infectivities"[All Fields] OR "infects"[All Fields] OR "pathogenicity"[Subheading] OR "pathogenicity"[All Fields] OR "infectivity"[All Fields] sub-Saharan Africa: "africa south of the sahara"[MeSH Terms] OR ("africa"[All Fields] AND "south"[All Fields] AND "sahara"[All Fields]) OR "africa south of the sahara"[All Fields] OR ("sub"[All Fields] AND "saharan"[All Fields] AND "africa"[All Fields]) OR "sub saharan africa"[All Fields]	
--	--	---	--

135

136 **iii. Eligible study selection**

137 The following criteria will be used to select relevant studies:

138 ***Inclusion criteria***

- 139 ✓ Studies reporting evidence of HIV/AIDS patients
- 140 ✓ Studies conducted among adults and children in SSA
- 141 ✓ Studies reporting evidence on CM diagnosis from CSF sample and CrAg
142 infection from whole blood, serum and plasma (CSF sample has the highest
143 diagnostic value irrespective of the blood sample result)
- 144 ✓ Studies reporting evidence on estimates of the incidence, prevalence, and
145 mortality of cryptococcal infection and CM
- 146 ✓ Studies reporting evidence on patients with historical cryptococcosis or overt
147 clinical CM

148 ***Exclusion criteria***

149 The following criteria will be used to exclude studies:

- 150 ✓ Studies reporting evidence other than whole blood, CSF sample, serum and
151 plasma
- 152 ✓ Studies reporting evidence of patients receiving antifungal treatment

- 153 ✓ Studies that report evidence of disease unrelated to CM (bacterial or viral
- 154 meningitis, tuberculous meningitis, protozoan infections, and space-occupying
- 155 cerebral oedema lesion e.g. tuberculoma, hydrocephalus or CNS malignancy)
- 156 ✓ Studies reporting evidence on primary studies conducted outside SSA
- 157 ✓ Studies that do not specify CM diagnosis, CrAg infection, or record of test
- 158 performed
- 159 ✓ Review articles

160 Following the electronic database search, the eligible studies will be transferred to
161 Endnote, a citation management software. The PI will work independently to screen
162 titles using the inclusion and exclusion criteria guide. The PI, with the assistance of an
163 independent co-screener will screen the abstracts. Disagreements between the two
164 screeners will be settled by a discussion until unanimity is reached. Screening of full
165 article will be conducted by the same set of screeners. Any discrepancies that emerge
166 after screening full articles will be settled by introducing a third screener. The degree
167 of agreement amongst the screeners after full article screening will be established
168 through calculating the Cohen's Kappa Statistics (19, 20). The process of the study
169 search decision will be guided by the PRISMA flow chart as demonstrated in figure 1
170 (16) to aid reporting of the scoping review.

171 **iv. Charting the data**

172 A data charting form as outlined in table 3, will be used to derive information from each
173 included study. Two independent reviewers will pilot test and modify the data charting
174 form.

175 **Table 3:** Data charting form

Author & Year of publication
Journal
Aim of study
Study population
Study setting (rural and urban)
Study location (sub-Saharan Africa)
Study design

Main findings
Other significant findings

176

177 **v. Collating, summarising and reporting the results**

178 Findings will be presented in two ways. Firstly, from numerical data on the incidence,
179 prevalence and mortality of the study population will be reported. Secondly, we will
180 produce tables and graphs based from thematic analysis that originate from the PCC
181 to guide a summary of themes to extract from findings in relation to answering the
182 study question.

183 **vi. Appraisal of quality of evidence**

184 The mixed method appraisal tool (MMAT) version 2018 will be utilized to appraise the
185 quality of empirical studies, these are primary research acquired from observation,
186 experimental or simulation of study methods i.e. quantitative, qualitative, and/or mixed
187 method studies (21). Appraisal of the included studies will be intended to assess the
188 objectives of the study, method, study design, candidate recruitment, data collected,
189 analysis of data, discovered results, and authors' discussions and conclusions to
190 ensure they are reliable, trustworthy and valid. The appraisal process will involve two
191 independent reviewers assessing the checklist and criterion based on methodology
192 according to the MMAT (21). A percentage score will be calculated to evaluate the
193 quality of studies selected as follows: i) $\leq 50\%$, will be low quality ii) 51–75%, will be
194 average quality and iii) 76–100%, will be considered as high quality.

195 **vii. Ethical considerations**

196 This scoping review involves synthesis of current evidence therefore ethical approval
197 is not necessary. However, since the study is being conducted for degree purposes,
198 ethical approval was sought. The study was ethically reviewed and approved
199 submitted to the University of Pretoria Research Ethics Committee (Approval number:
200 606/2022).

201 **Discussion**

202 Screening of the cryptococcal antigen is the preferred approach for identifying risk of
203 progression to disease when managing people presenting with advanced HIV infection

204 (2). Screening for CrAg in PLHIV, followed by pre-emptive antifungal treatment for a
205 positive screening are one of the WHO's recommendations for prevention of
206 progression to CM (2). Highly accurate CrAg POC tests have been used for disease
207 screening to help expedite treatment (9, 11).

208 This scoping review will exclude studies conducted outside SSA as they will not be
209 reflecting findings associated with the region of interest. Studies reporting evidence of
210 patients receiving antifungal treatment will also be excluded as they will be giving
211 evidence on people who have already been screened and not on the CrAg infection
212 among PLHIV. Furthermore, review articles will be excluded on literature from primary
213 studies conducted by other researchers. We anticipate that results of this scoping
214 review will guide future policy and practice aimed on improving the HIV management.

215 **Acknowledgement**

216 The authors acknowledge the support received from the University of Pretoria during
217 the development of this protocol. The authors would also like to thank the library
218 services for their assistance with optimising the search strategy.

219 **Supporting material**

220 S1 Figure 1: PRISMA-Scr flow chart

221 **References**

- 222 1. Tugume L, Rhein J, Hullsiek KH, Mpoza E, Kiggundu R, Ssebambulidde K, et al. HIV-Associated
223 Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts. *J Infect Dis*. 2019;219(6):877-83.
- 224 2. World Health Organization. Guidelines for the diagnosis, prevention, and management of
225 cryptococcal disease in HIV-infected adults, adolescents and children, March 2018: supplement to
226 the 2016 consolidated guidelines of the use of antiretroviral drugs for treating and preventing HIV
227 infection [Publications]. World Health Organization; 2018 [updated 2018]. Available from:
228 <https://apps.who.int/iris/handle/10665/260399>.
- 229 3. Longley N, Jarvis JN, Meintjes G, Boule A, Cross A, Kelly N, et al. Cryptococcal Antigen
230 Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study. *Clin Infect Dis*.
231 2016;62(5):581-7.
- 232 4. Li Y, Huang X, Chen H, Qin Y, Hou J, Li A, et al. The prevalence of cryptococcal antigen (CrAg)
233 and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell
234 counts < 200 cells/ μ L: evidence based on a meta-analysis. *BMC Infect Dis*. 2020;20(1):410.
- 235 5. Ford N, Meintjes G, Vitoria M, Greene G, Chiller T. The evolving role of CD4 cell counts in HIV
236 care. *Curr Opin HIV AIDS*. 2017;12(2):123-8.
- 237 6. Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, et al. CD4 Cell Count Threshold
238 for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-
239 analysis. *Clin Infect Dis*. 2018;66(suppl_2):S152-s9.

- 240 7. Otto SBJ, George PE, Mercedes R, Nabukeera-Barungi N. Cryptococcal meningitis and
241 immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to
242 second line antiretroviral therapy: a case report. *BMC Infect Dis.* 2020;20(1):68.
- 243 8. Rajasingham R, Wake RM, Beyene T, Katende A, Letang E, Boulware DR. Cryptococcal
244 Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. *J Clin Microbiol.*
245 2019;57(1).
- 246 9. Drain PK, Hong T, Krows M, Govere S, Thulare H, Wallis CL, et al. Validation of clinic-based
247 cryptococcal antigen lateral flow assay screening in HIV-infected adults in South Africa. *Scientific*
248 *Reports.* 2019;9(1):2687.
- 249 10. Govender NP, Roy M, Mendes JF, Zulu TG, Chiller TM, Karstaedt AS. Evaluation of screening
250 and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.
251 *HIV Med.* 2015;16(8):468-76.
- 252 11. Chukwuanukwu RC, Uchenna N, Mbagwu SI, Chukwuanukwu TO, Charles O. Cryptococcus
253 neoformans seropositivity and some haematological parameters in HIV seropositive subjects. *Journal*
254 *of Infection and Public Health.* 2020;13(7):1042-6.
- 255 12. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of
256 disease of HIV-associated cryptococcal meningitis: an updated analysis. *Lancet Infect Dis.*
257 2017;17(8):873-81.
- 258 13. National Institute for Communicable Disease. Cryptococcal antigen screening surveillance
259 report, South Africa, February 2017- July 2019 - Google Search 2022 [Available from:
260 https://www.google.com/search?q=Cryptococcal+antigen+screening+surveillance+report%2C+South+Africa%2C+February+2017+%E2%80%93+July+2019&rlz=1C1CAFB_enZA626ZA626&oq=Cryptococcal+antigen+screening+surveillance+report%2C+South+Africa%2C+February+2017+%E2%80%93+July+2019&aqs=chrome..69i57j69i59.1762438j0j4&sourceid=chrome&ie=UTF-8.
261
262
263
- 264 14. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International*
265 *Journal of Social Research Methodology.* 2005;8(1):19-32.
- 266 15. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implement*
267 *Sci.* 2010;5(1):1-9.
- 268 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
269 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71.
- 270 17. McGowan J, Straus S, Moher D, Langlois EV, O'Brien KK, Horsley T, et al. Reporting scoping
271 reviews-PRISMA ScR extension. *J Clin Epidemiol.* 2020;123:177-9.
- 272 18. Warkentien T, Crum-Cianflone NF. An update on Cryptococcus among HIV-infected patients.
273 *Int J STD AIDS.* 2010;21(10):679-84.
- 274 19. Hallgren KA. Computing Inter-Rater Reliability for Observational Data: An Overview and
275 Tutorial. *Tutor Quant Methods Psychol.* 2012;8(1):23-34.
- 276 20. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
277 *Biometrics.* 1977;33(1):159-74.
- 278 21. Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed
279 Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers.
280 *Education for Information.* 2018;34(4):285-91.